The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus
van Poppel, P.C.M., Gresnigt, M.S., Smits, P., Netea, M.G., Tack, C.J.Volume:
103
Language:
english
Journal:
Diabetes Research and Clinical Practice
DOI:
10.1016/j.diabres.2013.12.039
Date:
March, 2014
File:
PDF, 907 KB
english, 2014